OncoCipherPATIENT
Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.

← Cutaneous & Mucosal Melanoma Overview

Cutaneous & Mucosal Melanoma — All 36 Unranked Reference Options

Provenance SHA-256: 47ba5c2e2c1931eb · Protocol drug dosing hard-excluded in Patient Edition.

Option / Regimen FamilyCategory & StatusCurated Source IDs
Surgery and regional-node staging review
Review the recorded primary pathology, whether the definitive wide excision has been done, regional nodes and the need for a sentinel-node discussion. NCI summary for stage IA: “Excision with or without sentinel lymph node biopsy (SLNB).”
Local care
Care pathway
nci-melanoma, nci-melanoma-pdq-2025
Post-resection surveillance discussion
Plan individualized clinical, skin and regional-node follow-up; observation remains an explicit discussion.
Follow-up
Care pathway
nci-melanoma
Adjuvant pembrolizumab
Discuss postoperative anti-PD-1 therapy in the supported completely resected setting.
Systemic therapy
FDA-approved
keytruda-label, keynote716, kn716-final, kn054-7y
Adjuvant nivolumab
Discuss postoperative nivolumab after complete resection.
Systemic therapy
FDA-approved
opdivo-label, checkmate76k, checkmate238, cm76k-primary, cm238-9y, cm238-correction
Adjuvant dabrafenib plus trametinib
Discuss adjuvant BRAF/MEK inhibition for confirmed BRAF V600E disease.
Systemic therapy
FDA-approved
tafinlar-label, mekinist-spl, combiad-final
Review discordant adjuvant BRAF V600K evidence
Reconcile the broader US label with the guideline caution before any targeted adjuvant choice.
Specialist review
Care pathway
tafinlar-label, combiad-final
Neoadjuvant nivolumab plus ipilimumab, then response-guided review
Discuss the NADINA strategy before surgery in macroscopic nodal stage III disease.
Systemic therapy
Evidence-supported off-label
nadina, opdivo-label
Perioperative pembrolizumab
Discuss preoperative and postoperative pembrolizumab for clinically detectable, resectable disease.
Systemic therapy
Evidence-supported off-label
s1801, keytruda-label
Upfront surgery followed by adjuvant-treatment review
Discuss complete local treatment followed by an explicit postoperative systemic-treatment decision.
Local care
Care pathway
nci-melanoma, nadina, s1801
Nivolumab plus ipilimumab
Discuss combined PD-1/CTLA-4 blockade in untreated advanced cutaneous melanoma.
Systemic therapy
FDA-approved
opdivo-label, checkmate067-final, dreamseq, nct01844505
Nivolumab plus relatlimab
Discuss combined PD-1/LAG-3 blockade in untreated advanced disease.
Systemic therapy
FDA-approved
opdualag-label, relativity047
Nivolumab monotherapy
Discuss single-agent PD-1 treatment.
Systemic therapy
FDA-approved
opdivo-label, checkmate067-final, relativity047, nct01844505
Pembrolizumab monotherapy
Discuss single-agent pembrolizumab.
Systemic therapy
FDA-approved
keytruda-label, kn006-10y, nct01866319
Dabrafenib plus trametinib
Discuss BRAF/MEK inhibition after confirmation of the reported actionable variant.
Systemic therapy
FDA-approved
tafinlar-label, mekinist-spl, dreamseq
Encorafenib plus binimetinib
Discuss BRAF/MEK inhibition after confirmation of the reported actionable variant.
Systemic therapy
FDA-approved
mektovi-label, braftovi-spl, mektovi-spl, columbus-7y
Vemurafenib plus cobimetinib
Discuss BRAF/MEK inhibition after confirmation of the reported actionable variant.
Systemic therapy
FDA-approved
cotellic-label, zelboraf-spl, cobrim-5y
Nivolumab plus ipilimumab after PD-1 progression
Review combined checkpoint blockade in PD-1-refractory, CTLA-4-naive disease.
Systemic therapy
FDA-approved
opdivo-label, s1616
Lifileucel cell-therapy referral
Refer a potentially appropriate previously treated patient to a specialist cell-therapy center.
Systemic therapy
FDA accelerated approval
amtagvi-fda, amtagvi-review, amtagvi-label
Talimogene laherparepvec local treatment review
Discuss intralesional treatment of accessible recurrent cutaneous, subcutaneous or nodal lesions.
Local therapy
FDA-approved
imlygic-label
Multidisciplinary CNS/local-therapy review
Coordinate melanoma, radiation and neurosurgical assessment, including symptoms, corticosteroid use, earlier local treatment, lesion size and whether a lesion needs immediate treatment. Lesion-directed choices named by the NCI brain-tumour summary (not specific to melanoma): “The following treatments have been used in the management of metastatic brain tumors: Radiation therapy.Radiosurgery.Surgical resection.Corticosteroids.Anticonvulsants.” For one to four metastases: “Focal therapy alone (surgical resection or stereotactic radiosurgery).”
Specialist review
Care pathway
nci-cns-pdq-2025, nci-melanoma-pdq-2025
Sentinel-node biopsy discussion
Sentinel-node biopsy discussion with the melanoma surgical team. NCI summary: “Lymphatic mapping and SLNB for patients with high-risk, thin melanomas (≥0.8 mm) or ulcerated lesions measuring less than 0.8 mm may identify individuals with occult nodal disease. These procedures should be considered, particularly if other adverse prognostic features are present.”
Local care
Care pathway
nci-melanoma-pdq-2025, mslt1-final
Sentinel-node staging review
Sentinel-node biopsy discussion with the melanoma surgical team. NCI summary: “Lymphatic mapping and sentinel lymph node biopsy (SLNB) for patients who have tumors of intermediate thickness may identify individuals with occult nodal disease. Lymphatic mapping and SLNB should be considered to assess the presence of occult metastasis in the regional lymph nodes of patients with primary tumors measuring at least 0.8 mm thick with clinically negative nodes.”
Local care
Care pathway
nci-melanoma-pdq-2025, mslt1-final
Vusolimogene oderparepvec-wtpg plus nivolumab
Discuss the approved intratumoral oncolytic-virus combination after progression on a PD-1-based regimen.
Systemic therapy
FDA accelerated approval
tudriqev-label, tudriqev-fda
Adjuvant nivolumab plus ipilimumab (IMMUNED schedule)
A postoperative combination option for selected completely resected stage IV disease.
Systemic therapy
Off-label adjuvant combination; guideline-supported discussion for selected stage IV NED patients
immuned-final, immuned-csr
Pembrolizumab plus low-dose ipilimumab after PD-1 progression (off-label)
Off-label combination studied after progression on anti-PD-1 treatment. Pembrolizumab is labelled for unresectable or metastatic melanoma; the ipilimumab label names only nivolumab as its combination partner in melanoma.
Systemic therapy
Off-label combination; prospective phase II trial, 70 patients
olson-2021, nct02743819, keytruda-label, yervoy-spl
Adjuvant pembrolizumab after complete resection of stage IV (off-label)
Off-label for stage IV: “KEYTRUDA is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.” Nivolumab is the labelled adjuvant anti-PD-1 treatment for completely resected stage IV: “OPDIVO is indicated for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma.”
Systemic therapy
Off-label for stage IV; randomised phase 3 trial SWOG S1404 against interferon or ipilimumab
s1404-primary, nct02506153, keytruda-label, opdivo-label
Imatinib for KIT-mutated acral melanoma (off-label)
Off-label KIT-directed treatment studied in melanoma with a KIT mutation. Imatinib has no melanoma indication. “Melanomas that arise on mucosal, acral, or CSD skin should be assessed for KIT mutations.”
Systemic therapy
Off-label; three prospective phase 2 trials (43 patients enrolled; 28 treated; 25 enrolled)
guo-2011, carvajal-2011, hodi-2013, nct00424515, gleevec-spl, nci-melanoma-pdq-2025
Nivolumab plus ipilimumab with active brain metastases
The labelled combination for unresectable or metastatic melanoma, reviewed for active brain metastases together with the multidisciplinary CNS review. “OPDIVO, as a single agent or in combination with ipilimumab, is indicated for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma.”
Systemic therapy
FDA-approved indication; the label trial excluded active brain metastases (evidence limited)
opdivo-label, cm204-final, nct02320058, cm204-primary, abc-7y
Dabrafenib plus trametinib with active brain metastases
The labelled BRAF/MEK combination for BRAF V600E or V600K melanoma, reviewed for active brain metastases together with the multidisciplinary CNS review. “TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test”
Systemic therapy
FDA-approved indication; the label trials excluded active brain metastases (evidence limited)
tafinlar-label, mekinist-spl, combi-mb
Wide excision margin for the recorded thickness
Definitive wide excision after the diagnostic biopsy. “A biopsy, preferably by local excision, should be performed for any suspicious lesions.” “Localized melanoma is excised with margins proportional to the microstage of the primary lesion.” A clear margin on the diagnostic biopsy is not the definitive excision margin; record which specimen the margin belongs to.
Local care
Care pathway
nci-melanoma-pdq-2025
Tebentafusp-tebn (HLA-A*02:01-positive uveal melanoma)
Bispecific gp100 peptide-HLA-directed CD3 T-cell engager indicated for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
bispecific_immunotherapy
FDA-approved
kimmtrak-label, imcgp100-primary, imcgp100-3y
Melphalan percutaneous hepatic perfusion (HEPZATO KIT)
Liver-directed intra-arterial melphalan infusion via the HEPZATO KIT Hepatic Delivery System for adult metastatic uveal melanoma with unresectable hepatic metastases affecting <50% of the liver and absent or limited extrahepatic disease.
liver_directed_chemotherapy
FDA-approved (REMS)
hepzato-label, focus-hepzato
Nivolumab plus ipilimumab (metastatic uveal melanoma)
Dual PD-1 plus CTLA-4 checkpoint blockade evaluated in two prospective single-arm phase II metastatic uveal melanoma trials (MDACC NCT01585194 and Spanish GEM-1402 NCT02626962).
checkpoint_doublet
FDA-approved for unresectable or metastatic melanoma; prospective phase II uveal melanoma trials (GEM-1402, MDACC)
opdivo-label, yervoy-spl, pelster-2021, piulats-2021
Multidisciplinary uveal melanoma & liver-directed therapy review
Specialist ocular/uveal melanoma and hepatobiliary interventional review covering HLA-A*02:01 blood genotyping, liver MRI tumour-burden assessment, regional liver-directed eligibility, and clinical trials.
care_pathway
Care pathway
nci-uveal-pdq, imcgp100-primary, focus-hepzato
Anti-PD-1-based checkpoint immunotherapy (mucosal melanoma: nivolumab plus ipilimumab or anti-PD-1 monotherapy)
Systemic PD-1 blockade alone or combined with ipilimumab for unresectable or metastatic mucosal melanoma, contextualized with subtype-specific pooled prospective trial outcomes.
checkpoint_immunotherapy
FDA-approved for unresectable or metastatic melanoma; mucosal melanoma pooled trial analysis
opdivo-label, yervoy-spl, keytruda-label, dangelo-2017
Anatomic-site surgical & radiation multidisciplinary review (mucosal melanoma)
Head-and-neck, anorectal, or vulvovaginal surgical oncology, radiation oncology, and medical oncology review for mucosal melanoma staging, margin/local-control planning, and molecular profiling (KIT, BRAF, NRAS).
care_pathway
Care pathway
nci-melanoma, dangelo-2017